SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001078782-20-000417
Filing Date
2020-06-05
Accepted
2020-06-05 16:01:31
Documents
4
Period of Report
2020-06-04
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8K CURRENT REPORT f8k060420_8k.htm 8-K 32130
2 EXHIBIT 10.1 AMENDMENT NO. 1 DATED MARCH 31, 2020 TO ASSET PURCHASE AGREEMENT DA f8k060420_ex10z1.htm EX-10.1 7859
3 EXHIBIT 10.2 AMENDMENT NO. 2 DATED MAY 29, 2020 TO ASSET PURCHASE AGREEMENT DATE f8k060420_ex10z2.htm EX-10.2 7826
4 EXHIBIT 10.3 LICENSING AND DISTRIBUTION AGREEMENT DATED APRIL 27, 2020 BY AND BE f8k060420_ex10z3.htm EX-10.3 159499
  Complete submission text file 0001078782-20-000417.txt   208563
Mailing Address 109 AMBERSWEET WAY, #401 DAVENPORT FL 33897
Business Address 109 AMBERSWEET WAY, #401 DAVENPORT FL 33897 732-723-7395
MARIZYME INC (Filer) CIK: 0001413754 (see all company filings)

IRS No.: 825464863 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-53223 | Film No.: 20946092
SIC: 2834 Pharmaceutical Preparations